grant
Role of ATAD2 in Prostate Cancer Progression and Metastasis
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 1 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY202621+ years old2aR phosphoprotein I2ar peptideAddressAdultAdult HumanAffectAmerican maleAmerican manAmerican menBenignBindingBinding SitesBody TissuesBone MetastasisBone cancer metastaticBony metastasisBromodomainCancer CauseCancer EtiologyCancer PatientCancersCell BodyCell-Extracellular MatrixCellsCessation of lifeChromatinClinicalCombining SiteComplexCompressive MyelopathyDNADNA BindingDNA Binding InteractionDNA boundDataDeathDeoxyribonucleic AcidDetectable Residual DiseaseDevelopmentDiseaseDisorderDisseminated Malignant NeoplasmECMEnvironmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEta-1 proteinEta-1-Op proteinExperimental ModelsExtracellular MatrixFosteringFractureFrustrationFutureGEM modelGEMM modelGene TranscriptionGeneralized GrowthGenetic TranscriptionGenetically Engineered MouseGoalsGrowthHeterodimerizationHistone AcetylationHumanImmuneImmune EvasionImmune mediated therapyImmunesImmunocompetentImmunologically Directed TherapyImmunotherapyLinkLocalized DiseaseMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatorMetastasisMetastasis to boneMetastasizeMetastatic CancerMetastatic Cancer to the BoneMetastatic LesionMetastatic Malignant NeoplasmMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the BoneMetastatic Prostate CancerMetastatic TumorMetastatic Tumor to the BoneMetastatic malignant neoplasm to boneMiceMice MammalsMinimal Residual DiseaseMissionModelingModern ManMolecularMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryMorbidityMurineMusNeoplasm MetastasisOrganismOrganoidsOsseous metastasisOutcomeOutputPainPainfulPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPersonal SatisfactionPhenotypeProcessPrognosisProstate CAProstate CancerProstate Carcinoma MetastaticProstate malignancyProteinsPublic HealthQOLQuality of lifeRNA ExpressionReactive SiteReaderReportingResearchResidual NeoplasmResidual TumorsResistanceRoleSecondary NeoplasmSecondary TumorSecondary cancer of boneSecondary malignancy of boneSecondary malignant neoplasm of boneSiteSkeletal metastasisSurvival RateSystemTechnologyTestingTherapeuticTissue EngineeringTissue GrowthTissuesTranscriptionTumor CellTumor EscapeTumor Immune EscapeU.S. MalesUS MenUS maleadulthoodanti-tumor immune responsebioengineered tissuebiomarker drivenbonebone fracturebone neoplasm secondarybone sialoprotein 1bone sialoprotein Icancer carecancer evasioncancer immune escapecancer immune evasioncancer metastasiscancer progressioncancer typeclinical developmentconformationconformationalconformational stateconformationallyconformationsdevelopmentalearly T-lympocyte activation-1 proteinengineered tissueepigeneticallyepigenomicsextracellulargenetically engineered mouse modelgenetically engineered murine modelimmune competentimmune evasiveimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedinhibitorliving systemmales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmouse modelmultidisciplinarymurine modelneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachontogenyosteopontinoverexpressoverexpressionpatient oriented outcomesprogramsprostate cancer metastasisprostate cancer modelprostate cancer progressionprostate tumor modelresidual diseaseresistantresponse to therapyresponse to treatmentsecreted phosphoprotein 1sialoprotein 1social rolespinal cord compressiontargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapeutic targettherapy responsetreatment responsetreatment responsivenesstumor cell metastasistumor evasiontumor growthtumor immune evasiontumor progressionwell-beingwellbeing
Description preview
Prostate cancer remains the second-leading cause of cancer-related deaths in US men, mainly due to metastatic
disease. Metastasis occurs most frequently in bones, thus entailing significant patient morbidity including pain,
propensity to fractures and potential spinal cord compression. Moreover, the bone is a favored reservoir for
undetectable…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click